The latest report published by IMARC Group, titled “Benign Prostatic Hyperplasia Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028”, offers a comprehensive analysis of the industry, which comprises insights on the global benign prostatic hyperplasia treatment market share. The report also includes competitor and regional analysis, and contemporary advancements in the market. The market size reached US$ 11.3 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 15.5 Billion by 2028, exhibiting a growth rate (CAGR) of 5.2% during 2023-2028.
Industry Definition and Application:
Benign prostatic hyperplasia (BPH) refers to a common condition in men characterized by the enlargement of the prostate gland, leading to urinary symptoms including urgency, weak stream, and frequent urination. BPH treatment options incorporate minimally invasive procedures, surgery, and medications. Medications can help relieve symptoms by reducing the size of the prostate or relaxing the muscles in the prostate and bladder.
Minimally invasive procedures, including laser therapy and transurethral microwave thermotherapy, can also improve symptoms without surgery. Surgery, including transurethral resection of the prostate (TURP) or prostatectomy, may be recommended for severe cases of BPH or if other treatments have been ineffective. The choice of treatment depends on the severity of symptoms, the size of the prostate, and the individual’s overall health and preferences.
Global Market Trends and Growth Drivers:
The increasing prevalence of BPH among the aging male population represents a key factor driving the market growth across the globe. In line with this, governments of several countries, various healthcare organizations, and pharmaceutical companies are making efforts to increase awareness about BPH and encourage early diagnosis and treatment, which, in turn, is contributing to the growth of the market.
In addition to this, technological advancements in medical devices and surgical procedures are leading to the development of more effective and less invasive treatment options, which is creating a positive outlook for the market.
Competitive Landscape With Key Players:
The competitive landscape of the benign prostatic hyperplasia treatment market has been studied in the report with the detailed profiles of the key players operating in the market.
Some of these key players include:
- Abbott Laboratories
- Allergan Plc (AbbVie Inc.)
- Asahi Kasei Corporation
- Astellas Pharma Inc.
- Boehringer Ingelheim GmbH (C.H. Boehringer Sohn AG & Ko. KG)
- Boston Scientific Corporation
- GlaxoSmithKline Plc
- Pfizer Inc.
- Sanofi S.A.
- Teva Pharmaceutical Industries Ltd.
Key Market Segmentation:
The report has segmented the global benign prostatic hyperplasia treatment market based on treatment type and region.
Breakup by Treatment Type:
- Drug Class
- Alpha-Blockers
- 5-Alpha-reductase Inhibitors (5-ARIs)
- Phosphodiesterase-5 Enzyme Inhibitors
- Others
- Minimally Invasive Surgeries
- Transurethral Resection of the Prostate (TURP)
- Transurethral Incision of the Prostate (TUIP)
- Transurethral Microwave Thermotherapy (TUMT)
- Robotic Surgeries
- Prostatic Urethral Lifts
- Others
- Laser Therapy
- Others
Breakup by Region:
- North America
- Asia Pacific
- Europe
- Latin America
- Middle East and Africa
Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/benign-prostatic-hyperplasia-treatment-market
Key Highlights of the Report:
- Market Performance (2017-2022)
- Market Outlook (2023-2028)
- Market Trends
- Market Drivers and Success Factors
- Impact of COVID-19
- Value Chain Analysis
- Comprehensive mapping of the competitive landscape
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Media Contact:
Company Name: IMARC Group
Contact Person: Elena Anderson
Email: sales@imarcgroup.com
Phone: +1-631-791-1145
Address: 134 N 4th St
City: Brooklyn
State: NY
Country: United States
Website: https://www.imarcgroup.com/